All In Biotech

Drug Trial Radar · NCT03168139

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Jul 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Apr 18, 2017

Primary completion

Mar 25, 2020

Study completion Mar 25, 2020

Sponsor

Lead sponsor
TME Pharma AGIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular checkpoint inhibitors.

Conditions

  • Metastatic Colorectal Cancer
  • Metastatic Pancreatic Cancer

Interventions

  • Olaptesed pegol - MonotherapyDrug

    Monotherapy (MT) period: Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks

  • Olaptesed pegol + Pembrolizumab - Combination TherapyDrug

    Combination therapy (CT) period: Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monotherapy: PharmacodynamicsTime frame: up to 14 days
  2. Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratoryTime frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

    Heidelberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.